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Introduction and objectives: Bipolar plasma vaporization (BPV) has been introduced as an 
alternative to transurethral resection of the prostate (TURP). Promising short-term results but 
inferior mid-term results compared to TURP have been reported following first-generation 
bipolar electro-vaporization. Outcome data following second-generation BPV is still scarce. 
The aim of this investigation was to evaluate the intra- and post-operative outcome of 
contemporary BPV in a center with long-standing expertise on laser vaporization of the prostate.  
Methods: A consecutive series of 83 patients undergoing BPV in a tertiary referral center was 
prospectively evaluated. The investigated outcome parameters included the maximum flow 
rate (Qmax), postvoid residual volume, IPSS / Qol and PSA tests. Follow-up investigations 
took place after six weeks, six months and twelve months. Wilcoxon signed-rank test was 
used to compare pre- and post-treatment parameters.  
Results: The median (range) pre-operative prostate volume was 41ml (17-111ml). The pre-
operative IPSS, Qol, Qmax and residual volume were 16 (2-35), 4 (0-6), 10.1ml/sec (3-
29.3ml/sec) and 87ml (0-1000ml), respectively. One third of the patients were undergoing 
platelet aggregation inhibition. No intra-operative complications occurred. Post-operatively, 
13 patients (15.7%) had to be re-catheterized. Three patients (3.6%) had clot retention and 28 
patients (34%) reported any grade of dysuria. After six weeks, all outcome parameters 
improved significantly and remained improved over the twelve months observation period 
(IPSS: 3 (0-2); Qol: 1 (0-4); Qmax: 17.2ml/s (3.2-56ml/s); residual volume 11ml (0-190ml)). 
The PSA-reduction was 60% at study conclusion. Three patients (3.6%) developed a urethral 
stricture and four patients (4.8%) bladder neck sclerosis. Re-resections were not necessary.  
Conclusions: Contemporary BPV is a safe and efficacious treatment option even for patients 
undergoing platelet aggregation inhibition. Early urinary retention and temporary dysuria 
seem to be specific side effects of the treatment. Bleeding complications are rare. Long-term 
follow-up is needed to confirm these promising short-term results.  
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Introduction 
 
Monopolar transurethral resection of the prostate (TURP) has been shown to be an efficacious 
and durable treatment option for patients with lower urinary tract symptoms caused by prostatic 
enlargement
1-3
. It is considered the surgical reference standard for patients with a prostate volume 
of less than 80ml
4
. However, despite many technical refinements over the last decades it is still 
associated with a relevant rate of complications mainly caused by bleeding and the so-called 
TUR-syndrome
2, 5, 6
. The morbidity of TURP and the growing number of patients with significant 
cardiovascular co-morbidities or with an imperative indication for platelet aggregation inhibition 
(PAI) or anti-coagulation prompted the development of novel, minimally invasive alternatives. 
Bipolar TURP and 532nm laser vaporization are two safe and efficacious minimally invasive 
treatment options. They both are characterized by improved hemostatic properties and the 
possibility to perform intra-operative irrigation with isotonic saline. A lower rate of bleeding 
complications compared to conventional TURP and excellent clinical outcomes have been 
reported for these procedures
7-9
. Prostate vaporization using the 532nm laser is even safe in 
patients undergoing PAI or anti-coagulation
10
.  
Bipolar plasma vaporization (BPV) of the prostate has been introduced to further improve the 
hemostatic properties of bipolar TURP. Contemporary BPV using a hemispherical 
vaporization electrode combines the advantages of the bipolar technique (affordable 
equipment, saline irrigation) with the benefits of the 532nm laser technique (tissue 
vaporization, reduced bleeding, excellent overview and short learning curve). However, 
outcome data following contemporary BPV of the prostate is still scarce. Initial reports are 
very promising with low intra- and peri-operative morbidity and functional short-term results 
comparable or even superior to TURP
11-13
. The aim of the present investigation was to 
evaluate the intra-, peri- and postoperative outcome of the initial BPV series of our center, 
which has a long-standing expertise on prostate vaporization using the 532nm laser. 
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Patients and methods 
A consecutive series of patients undergoing BPV for prostatic bladder outlet obstruction in a 
tertiary referral centre between August 2009 and November 2011 was prospectively 
evaluated. Approval for this observational study was obtained from the local ethics committee 
and all enrolled patients provided written informed consent. 
The attending urologist generally made the indication for BPV after unsuccessful medical 
treatment or if the patient had refused medical therapy for his symptomatic prostatic bladder 
outlet obstruction. BPV was offered to all patients without PAI or anticoagulation but also to 
those undergoing PAI.  
Pre-operatively, patients were asked to complete the International Prostate Symptom Score 
(IPSS) and quality of life (Qol) questionnaire. Transrectal ultrasound of the prostate, 
uroflowmetry and postvoid residual volume measurement were performed. The pre-operative 
blood work included a prostate specific antigen (PSA) test. Patients with a PSA value >4 
ng/ml or a suspicious digital rectal examination underwent BPV only if a pre-operative 
prostate biopsy showed no malignant results. Urinalysis and a urine culture were also 
routinely performed. 
All patients with a normal pre-operative urine status received intravenous single-shot 
antibiotic prophylaxis with Trimethoprim-Sulfametoxazole 160/80mg 30-60 minutes prior to 
the operation. In patients with significant leukocyturia, antibiotic treatment was initiated pre-
operatively and continued for at least five days after catheter removal.  
The procedure was carried out under either general or spinal anesthesia. A SurgMaster UES-
40 generator and the hemispherical bipolar HF-vaporization electrode were used in 
combination with a 24-F OES continuous-flow Iglesias resectoscope (all Olympus Winter & 
Ibe GmbH, Hamburg, Germany). The power output used for tissue vaporization and tissue 
coagulation was 290-320W and 150-170W, respectively. The operation was performed using 
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the vaporization mode and coagulation was only used selectively for localized bleeding. All 
procedures were carried out under continuous low-pressure irrigation using an automated 
irrigation-suction pump (Endo Fluid Management System Urology, Future Medical System 
SA, Genève, Switzerland) and pre-warmed isotonic saline (37°C). 
The operation was carried out analogous to a conventional TURP. After insertion of the 
cystoscope and careful inspection of the prostate and bladder, the ureteral orifices were 
identified. Vaporization was initiated at the bladder neck to ablate the median lobe of the 
prostate. The procedure was continued at the lateral lobes. Finally, the anterior part of the 
prostate and the apical / para-collicular region were vaporized until the appearance of a 
TURP-like cavity. Extensive coagulation of the cavity at the end of the operation was 
generally avoided.  In patients with a prostate volume of less than 30ml an additional bladder 
neck incision was regularly performed. At the end of the procedures a 20-F three-way 
irrigation catheter was inserted and continuous irrigation with isotonic saline was initiated. 
The operative time (from insertion of the cystoscope to insertion of the catheter), the total 
amount of irrigation fluid and all intra-operative complications were recorded.  
Generally, the catheter was removed after three days. In the case of persisting hematuria, 
catheter-removal was postponed. After removal of the catheter uroflowmetry and postvoid-
residual volume measurements were done. Peri-operative complications, the duration of 
catheterization as well as re-catheterizations were recorded. 
The patients were regularly seen in follow-up after six weeks, six months and twelve months 
in the outpatient clinic. At each follow-up visit uroflowmetry, residual volume measurements 
and a PSA test were performed. Additionally, the IPSS and Qol questionnaire was completed. 
Furthermore, the patients were asked to report symptoms of dysuria.  
All data are presented as median and range. Statistical analysis was done using IBM SPSS 
Statistics software 20.0 (IBM, Armonk, NY, USA). The pre-operative variables were 
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 6 
compared to post-operative variables using the Wilcoxon signed-rank test. All p-values <0.05 
were considered statistically significant.  
 
Results 
A total of 83 patients were included in this study. The pre-operative patients characteristics 
are displayed in Table 1. Twenty-six patients (31.3 %) were operated under ongoing PAI with 
acetylsalicylic acid. One patient had dual PAI with additional clopidrogel medication. In all 
six patients with oral anticoagulation the coumarin medication was peri-operatively replaced 
by low molecular weight heparin at therapeutical doses. Heparin was stopped 24 hours before 
the operation and re-initiated with sub-therapeutical doses after the procedure. It was then 
gradually increased and replaced by coumarin if no macrohematuria occured.  
All patients underwent the pre-operative, initial post-operative and six weeks assessment. A 
total of 75 (90%) and 71 (86%) patients were available for the evaluation after six and twelve 
months, respectively. 
The intra- and peri-operative results are shown in Table 2. BPV was performed by a total of 
five surgeons. Three senior surgeons did 67 procedures (81%) and two senior residents did 16 
supervised procedures (19%) in form of a teaching operation. Pure BPV was successfully 
completed in 82 patients (98.8%). Conversion to conventional bipolar TURP was necessary in 
one patient with a prostate volume of 110ml due to intra-operative diffuse hemorrhage, which 
resulted in poor visibility. The patient was not undergoing PAI but was under antibiotic 
therapy for an asymptomatic urinary tract infection. Major intra-operative complications did 
not occur and intra- or peri-operative blood transfusions were not necessary in any of the 
patients.  
A total of 32 patients (36%) had a positive pre-operative urine culture. Nine of these patients 
had an unsuspicious urine status. Post-operatively, a positive urine culture was found in nine 
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 7 
patients who subsequently were treated with antibiotics. Only one of these patients had an 
indwelling catheter pre-operatively. None of the patients developed symptoms of a systemic 
urinary tract infection or an urosepsis.  
Four of the thirteen patients who needed post-operative re-catheterization had an indwelling 
catheter pre-operatively. Three patients were discharged with a catheter of which two were 
successfully removed after thirteen days. In one patient with persistent urinary retention a 
suprapubic cystostomy was performed for permanent solution. Peri-operatively, one patient 
developed gross hematuria with clot retention. Following cystoscopic clot evacuation 
transurethral coagulation of the ablation cavity was undertaken. One patient developed a 
small bowel volvulus associated with an adhesive strangulation three days after the operation. 
After laparotomy a segment resection and entero-enterostomy was performed. Seven days 
later an anastomotic leak was detected and a revision of the entero-enteostomy was necessary. 
The patient was discharged 36 days after BPV.  
Table 3 summarizes the post-operative outcome parameters. The maximum flow rate (Qmax) 
and the residual volume were already investigated after catheter removal. The Qmax 
increased non-significantly to 14ml/s (p=0.06), whereas the reduction of the residual volume 
was already statistically significant at this early post-operative assessment (p<0.001). After 
six weeks all functional outcome parameters improved significantly compared to the baseline 
values (Wilcoxon p<0.001 (IPPS, Qol, residual volume) and Wilcoxon p=0.006 (Qmax)). A 
further significant improvement was detectable after six months for the IPSS and Qol and 
after twelve month for the IPSS. All parameters remained significantly improved over the 
entire twelve months observation period (Table 3). The PSA value was already significantly 
reduced after six weeks (p<0.001). After twelve months a 60% reduction of the initial PSA 
value was detectable (Table 3).  
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Table 4 illustrates further post-operative results. Of the 15 patients who were found to have a 
positive urine culture six weeks after surgery, six had an indwelling catheter and ten a positive 
urine culture pre-operatively. All patients were treated with oral antibiotics. One patient was 
diagnosed with a pyelonephritis one month after the operation. The urine was found to be 
positive for mycobacterium tuberculosis. An initial four-drug regimen was followed by a 
three-drug treatment for nine months. Subsequently, mycobacteria were not detectable 
anymore. Four patients were diagnosed with a urinary tract infection between the six weeks 
and six months follow-up. Afterwards, urinary tract infections were not diagnosed anymore.  
Two patients (2.4%) presented with delayed hematuria and clot retention after four and six 
weeks, respectively. Both patients were hospitalized for cystoscopic clot evacuation and 
subsequent coagulation. One of these patients was undergoing dual PAI medication and 
therefore, laser coagulation of the ablation cavity was performed. In three symptomatic 
patients (4%) a de novo urethral stricture was diagnosed and treated by visual internal 
urethrotomy after six and eight months and by a simple dilatation procedure after eleven 
months, respectively. All of the four patients who developed a symptomatic bladder neck 
sclerosis were treated by transurethral bladder neck incision after 2 months (n=1) four months 
(n=2) and seven months (n=1), respectively. Only one of the patients had an initial prostate 
volume of less than 30ml and none of the patients had a urinary tract infection pre- or post-
operatively.  
 
Discussion 
This prospective investigation of intra-, peri- and post-operative outcomes following pure 
contemporary BPV of the prostate revealed that the procedure is safe, has a low morbidity and 
results in significant improvements of all investigated outcome parameters. No major intra-
operative complications occurred and conversion to conventional bipolar transurethral 
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 9 
resection was necessary in only one patient with a large prostate. Post-operative bleeding 
complications, which required re-interventions but no transfusions, occurred in three patients 
of whom one was undergoing dual PAI. Interestingly, two of these complications occurred 
with a delay of four to six weeks after the operation. Urinary tract infections were relatively 
frequent pre-operatively but also in the early post-operative period. One third of the patients 
reported dysuria after six weeks. After 6 months urinary symptoms were generally rare. Re-
operations due to persistent obstructive tissue were not necessary but seven patients (8%) 
were treated for symptomatic urethral strictures (n=3) or bladder neck sclerosis (n=4).  
Kaplan and Te introduced electro-vaporization of the prostate using a rollerball electrode in 
1995
14
. Despite promising functional results, this monopolar technique was soon abandoned 
due to higher rates of irritative voiding symptoms and stress urinary incontinence compared to 
conventional TURP
11, 15
. In 2001 Botto and colleagues reported their initial results of a 
bipolar vaporization technique using a special bar electrode
16
. Subsequently several studies 
revealed a lower intra- and perioperative morbidity and functional short-term results 
comparable to conventional TURP
17-20
. However, mid-term results have been reported to be 
inferior compared to TURP
7, 21
.  
In 2008 a novel bipolar device using an ergonomic, hemispherical electrode and a different 
energy setting was launched
22
. To date, only limited data is available for this contemporary 
BPV technique. In 2010 Reich and colleagues reported their initial clinical experience of a 
very small series of 30 patients with a follow-up of six months
11
. Four different surgeons 
from two centers did the operations. Their short-term functional results were comparable to 
the results of the present study. Bleeding complications did not occur and one patient with a 
large initial prostate volume required a re-operation four weeks after the initial procedure.  
Robert and colleagues reported a French multicenter observational study of 106 consecutive 
patients with a short-term follow-up of three months
13
. Patients were recruited from eight 
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different centers. A maximum of three surgeons per center performed the operations resulting 
in an average of only seven operations per surgeon. Improvements of the IPSS and bother 
score were comparable to the improvements observed in the present study. However a high 
failure rate of eight percent after three months indicates that tissue ablation might have been 
insufficient in a relevant proportion of patients in this study. Additionally, three major 
complications (urethral necrosis with urinary fistulas (n=2) and significant bladder necrosis 
(n=1)) occurred in three consecutive patients from one center. These complications were 
considered to be associated with material failure. The case of a small bowel volvulus 
requiring a segment resection represents a serious complication in our series. It is likely that 
the development of the volvulus is somehow related to the initial surgery. However, we do 
not believe that this complication is specifically related to the BPV procedure.  
The same group from France reported a post-hoc retrospective comparison of 54 patients 
under oral anticoagulation from their initial study and 57 patients undergoing TURP under 
oral anticoagulation
23
. Comparable functional results after three months but significantly less 
bleeding complications after BPV were seen. It is noteworthy that most of the patients were 
not under oral anticoagulation but under PAI. Furthermore, PAI was stopped in the majority 
of the patients and oral anticoagulation was replaced by heparin in all patients prior to 
surgery. In the present investigation, 30% of the patients were under ongoing PAI. Intra-
operative bleeding complications did not occur in these patients. However, dual PAI and 
urinary tract infections might increase the risk of intra- and perioperative bleeding 
complications.  
Two randomized-trials comparing BPV with monopolar and bipolar TURP were conducted 
by Geavlete and colleagues
12, 24
. In their first study they reported six-months results of 155 
patients undergoing either BPV (n=75) or monopolar TURP (n=80) done by a single 
surgeon
24
. The operative time, catheterization period and hospital stay were significantly 
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shorter in the BPV arm. Furthermore, all relevant outcome parameters were in favor of BPV 
and the complication rate was significantly lower following BPV compared to TURP. The 
mean operative time was 35.1min and the mean prostate volume decreased from 56.2ml to 
16.8ml after six months. Compared to the present investigation, the Qmax in their study was 
slightly higher and the re-catheterization rate and dysuria rate lower. Urethral strictures and 
re-operations were not reported.  
The second trial by the same group indicated to evaluate long-term results of a randomized 
trial of 510 patients who underwent BPV (n=170), monopolar TURP (n=170) and bipolar 
TURP (n=170)
12
. However, with a follow-up of only 18-months, we think that the results of 
this trial represent rather short-term than long-term results. This large-scale single center trial 
revealed a clear benefit for BPV in terms of complications and clinical outcome. The intra-
operative complication rate was significantly lower in the BPV arm compared to both, the 
monopolar and the bipolar TURP arm. Post-operative irritative voiding symptoms and 
urethral strictures were comparable between the three groups. However, a significantly lower 
re-catheterization rate, a lower rate of bladder neck sclerosis and fewer re-treatments were 
detectable following BPV. Furthermore, improvements of IPSS, Qol and Qmax were 
significantly better in the BPV arm. It remains unclear why the bipolar TURP arm and the 
additional 95 and 90 patients in the BPV and monopolar TURP arm, respectively, were not 
reported in the initial series which was published only 12 months earlier. Long-term follow-
up will show if these excellent results are durable.  
In the present study the duration of catheterization was significantly longer compared to the 
other studies
11, 13, 24
. This difference is not related to a higher rate of bleeding complications 
but is mainly due to local reimbursement policies in Switzerland. The present investigation 
also revealed a lower Qmax compared to the studies by Geavlete and colleagues
12, 24
. The 
improvement of the Qmax in the present investigation is comparable to what has been 
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reported in the studies by Reich and Robert, respectively
11, 13
. However, it seems also to be 
significantly lower than the improvement reported following monopolar TURP
7, 24
. All other 
investigated functional outcome parameters are comparable to the results reported after BPV 
and monopolar TURP. The studies of Geavlete and colleagues also showed a lower 
complication rate compared to the present investigation. We found more urinary tract 
infections, re-catheterizations and higher rates of dysuria and bladder neck sclerosis. Dysuria, 
early post-operative urinary retention and urinary tract infections have been reported to be 
frequent after 532nm laser vaporization of the prostate
7
. The higher rate of these 
complications in the present study might indicate that these complications are associated with 
prostate vaporization in general. Given the wide range of the reported rate of bladder neck 
sclerosis following BPV among different studies (0.6% to 7.2%), the rate in the present study 
appears to be rather average
12, 25
. Furthermore, it seems to be comparable to what has been 
reported for monopolar and bipolar TURP
26, 27
. In our collective, re-treatments were not 
necessary during the twelve months observation period. This is lower compared to published 
BPV and TURP data. A longer follow-up has to confirm this promising result.  
The generally excellent coagulation properties of the bipolar vaporization device result in an 
excellent overview during the procedure and, in our opinion, make this treatment modality 
particularly appealing for teaching operations. However, we also realized that the procedure 
has to be performed in a speedy manner in order to achieve sufficient tissue ablation in a 
reasonable time. The experience of the surgeon is likely to influence the speed and efficiency 
of tissue vaporization during BPV. In the study by Geavlete, a single surgeon did all 
procedures. This might explain the excellent ablation rate of approximately 40ml in 35 
minutes and the above-average clinical outcome
24
. The high retreatment rate in the French 
study might reflect the insufficient tissue ablation of surgeons who were rather inexperienced 
using this technique
13
. All senior surgeons in the present study were experienced in prostate 
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vaporizations using the 532nm laser. This experience might improve the vaporization 
efficiency particularly in the learning phase of the BPV procedure. The PSA reduction of 60% 
and the lack of necessity for re-operations substantiate this assumption.  
A drawback of the present investigation is the lack of a control group, which limits the ability 
to compare the results with those of other techniques. However, given the sparsely available 
data of contemporary BPV, our study adds important information to the published evidence. 
Furthermore, we did not design and power this study for subgroup analyses, which might 
allow identifying predictors of clinical outcome following BPV. A larger prospective 
investigation would be required to formally identify these predictors and our results can be 
helpful in designing such a study. The long-standing experience with prostate vaporization 
techniques in our center, the longer follow-up period, the larger number of patients and the 
lower number of surgeons who performed the procedure compared to most of the other BPV 
studies are specific advantages of our investigation.  
 
Conclusion 
Contemporary BPV is a safe and efficacious treatment option even for patients undergoing 
PAI. BPV results in significant improvements of all relevant outcome parameters over a 
twelve months period. Bleeding complications are rare. Early urinary retention and temporary 
dysuria seem to be specific side effects of the treatment. A multi-institutional study with long-
term follow-up is needed to confirm the promising short-term results and to further evaluate 
the durability of the procedure.  
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Table 1 - Baseline patient characteristics 
 
Number of patients 83 
Age (y) 67 (48 – 89) 
Prostate volume (ml) 41 (17 – 111) 
PSA (ng/ml) 2.69 (0.26 – 22.5) 
IPSS 16 (2 – 35) 
QoL 4 (0 – 6) 
Qmax (ml/s) 10.1 (3 – 29.3) 
Residual volume (ml) 87 (0 – 1000) 
Indwelling catheter (n) 20 (24.1%) 
ASA score 
 
        1 
        2 
        3 
2 (1-3) 
 
        8     (9.6 %) 
        50  (60.2%) 
        25  (30.1%) 
Coagulation modifiers (n) 
        Acetylsalicylic acid (n) 
        Clopidrogel (n) 
        Coumarine (n) 
        Dual therapy (n) 
26 (31.3%) 
        26 (31.3%) 
          1 (1.2%) 
          0 (0%) 
          1 (1.2%) 
Positive urine culture  (n) 
        Indwelling catheter (n) 
        No catheter (n) 
32 (38.5%) 
         18 (21.6%) 
         14 (16.8%) 
 
Data presented as median (range) or number (percent).  
PSA = prostate-specific antigen, IPSS = International Prostate Symptom score, QoL = Quality of life, 
Qmax = Maximum flow rate, ASA score = American Society of Anaesthesiology score.  
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Table 2: Intra- and peri-operative results 
 
 
Operative time (min) 80 (34-145) 
Irrigation volume (l) 22.5 (12-39) 
General anesthesia (n) 
Spinal anesthesia (n) 
60 (72.2%) 
23 (27.8%) 
Blood transfusion (n) 0 (0%) 
Duration of catheterization (d) 3 (2-13) 
Duration of hospitalization (d) 4 (2-11) 
Re-catheterization (n) 
        Urinary retention (n) 
        High residual volume + UTI (n) 
        Clot retention (n) 
13 (15.6%) 
        10 (12%) 
          2  (2.4%) 
          1  (1.2%)  
Data presented as median (range) or number (percent).  
UTI = urinary tract infection 
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Table 3: Baseline and post-operative outcome parameters 
Parameter Baseline Post-operative 6 weeks 6 months 12 months 
 
IPSS 16 (2 – 35) N/A 8* (0 – 29) 3*° (0 – 24) 3*° (0 – 20) 
QoL 4 (0 – 6) N/A 2* (0 – 6) 1*° (0 – 4) 1* (0 – 4) 
Qmax (ml/s) 10.1 (3 – 29.3) 14.0 (3.8 – 47) 16.7* (2.3 – 52) 16.7* (5 – 53.8) 17.2* (3.3 – 56) 
Residual volume (ml) 87 (0 – 1000) 20* (0 – 900) 10* (0 – 437) 6.5* (0 – 500) 11* (0 – 190) 
PSA (ng/ml) 2.69 (0.26 – 22.5) N/A 1.36* (0.04 –9.56) 1.27* (0.15 – 6.98) 1.11* (0.08 – 7.18) 
 
Data presented as median (range) 
IPSS = International Prostate Symptom score, QoL = Quality of life, Qmax = Maximum flow rate, PSA = prostate-specific antigen, N/A = 
not applicable 
* indicates a statistically significant improvement compared to the baseline value (Wilcoxon signed-rank test) 
° indicates a statistically significant improvement compared to the preceding assessment  (Wilcoxon signed-rank test) 
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Table 4: Post-operative results 
 
Urinary tract infection  
        ≤ 6 weeks (n) 
        6 weeks – 6 months (n) 
        6 months – 12 months (n) 
 
15 (18%) 
  4 (4.8%) 
  0 (0%) 
Delayed clot retention (≤ 6 weeks; n) 2 (2.4%) 
Dysuria  
        6 weeks (n) 
        6 months (n) 
        12 months (n) 
 
        28 (34%) 
          2 (2.4%) 
          3 (3.6%) 
Urethral stricture (n) 3 (3.6%) 
Bladder neck sclerosis (n) 4 (4.8%) 
Re-resection (n) 0 (0%) 
Data presented as median (range) or number (percent).  
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